Study finds continued reduction in breast cancer incidence associated with longer use of raloxifene
Raloxifene (Evista) continues to be associated with more than a 50% reduction in breast cancer incidence beyond the first 4 years of treatment, according to a new study in the December 1 issue of the Journal of the National Cancer Institute.
The randomized, double-blind Multiple Outcomes of Raloxifene Evaluation (MORE) trial found that, in postmenopausal women with osteoporosis, 4 years of treatment with raloxifene was associated with a 72% reduction in breast cancer incidence compared with placebo. The Continuing Outcomes Relevant to Evista (CORE) trial was designed to examine the effect of an additional 4 years of treatment with raloxifene in the same group of women.
In the CORE trial, more than 4,000 women who had been part of the MORE trial continued taking either 60 mg/day of raloxifene, if they had been assigned to the raloxifene group in the MORE trial, or a placebo, if they had been assigned to the placebo group.
Silvana Martino, D.O., of the Cancer Institute Medical Group in Santa Monica, Calif., and colleagues report that, after the 4 years of the CORE trial, incidence of invasive breast cancer for women taking raloxifene was reduced by 59% compared with women taking the placebo, and incidence of estrogen-receptor (ER)-positive invasive breast cancer was reduced by 66%. Over the entire 8 years of MORE and CORE, the incidence of invasive breast cancer and ER-positive invasive breast cancer were reduced by 66% and 76%, respectively. There was no difference between the two groups in incidence of either ER-negative invasive breast cancer or noninvasive breast cancer. In both the MORE and CORE trials, there was a twofold increase in venous thromboembolic events, such as pulmonary embolism, among women taking raloxifene.
"[T]hese data demonstrate that the incidence of ER-positive invasive breast cancer continues to be reduced through 8 years of raloxifene treatment in postmenopausal women with osteoporosis," the authors write. "The effect of raloxifene on breast cancer incidence is currently being evaluated in postmenopausal women at high risk for heart disease in the Raloxifene Use for The Heart (RUTH) trial and in postmenopausal women at high risk for breast cancer in the STAR [Study of Tamoxifen and Raloxifene] trial."
In an editorial, Powel Brown, M.D., Ph.D., of the Baylor College of Medicine in Houston, and colleagues note that the effect of raloxifene treatment in the CORE trial may be confounded by several factors, but write that the results of the CORE and MORE trials support the conclusion that raloxifene reduces the risk of breast cancer. However, the authors write, "For women without osteoporosis who are at high risk of breast cancer, tamoxifen, in our opinion, remains the 'gold standard' chemoprevention agent to reduce the risk of breast cancer in high-risk pre- and postmenopausal women. We anticipate that the results of several large-scale chemoprevention trials will help clarify the role of raloxifene, as well as other hormonal agents, for breast cancer prevention."
Article: Darlene Ford, Cancer Institute Medical Group, 310-582-7907, [email protected]
Editorial: Kimberlee Barbour, Office of Public Affairs, Baylor College of Medicine, 713-798-7971, [email protected]
Article: Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. J Natl Cancer Inst 2004;96:1751–61.
Editorial: Kalidas M, Hilsenbeck S, Brown P. Defining the Role of Raloxifene for the Prevention of Breast Cancer. J Natl Cancer Inst 2004;96:1731–33.
Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oupjournals.org/.